Following AstraZeneca’s December announcement that it is taking steps to reintroduce the EGFR-targeted non-small cell lung cancer drug Iressa (gefitinib) in the US, Qiagen said last week that it would develop a tissue-based molecular diagnostic test to accompany the drug’s launch.
{iframe}https://www.genomeweb.com/regulatory-news/astrazeneca-qiagen-continue-advance-personalized-rx-cdx-partnership-around-iressa{/iframe}